Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its PARP inhibitor, stenoparib, against Coronavirus variant B.1.1.7 (British variant). The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.
Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials
Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network
Viroclinics Biosciences B.V.